Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists unmask bacterial evasion tactics in immune study

NCT ID NCT00339287

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 17, 2026 · Updated 13 times

Summary

This study aims to understand how certain bacteria avoid being killed by our immune cells, leading to infections. Researchers will collect blood samples from 200 healthy adults to study these interactions in the lab. The goal is to learn more about how bacteria cause disease and how our immune system responds, which could inform future treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2001

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Volunteers will be selected from a healthy adult population, 21-65 years of age, with no known medical problems and will generally be NIH employees working at Rocky Mountain Laboratories (RML) or within the community of Hamilton, MT. No race or gender is excluded from the donor pool and reflects the diversity of the community and that of the employees at RML.

Ages

18 to 120 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION \& EXCLUSION CRITERIA: Volunteers will be selected from a healthy adult population, 18 years of age or older, with no known medical problems and will generally be NIH employees working at Rocky Mountain Laboratories (RML) or within the community of Hamilton, MT. No race or gender is excluded from the donor pool and reflects the diversity of the community and that of the employees at RML. The specific criteria for eligibility are as follows: * Subjects must fit the definition of "healthy adults" as assessed by the medical/health screening evaluations, and willing to have blood and/or tissue samples stored for future use. * Inasmuch as all subjects are RML employees, they will be 18 years of age or older. * Children are excluded. * Pregnant women will be identified by verbal history and are not eligible to donate blood for this protocol. * The study population will be all-inclusive except in certain instances where individuals possess genetic defects that impair phagocyte function (e.g., myeloperoxidase-deficiency) or have altered phagocyte function due to outside influences such as recent bacterial or viral infection. * Individuals below the normal hematocrit and hemoglobin ranges will be excluded from the protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Host defense mechanisms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • NIAID, Rocky Mountain Laboratories

    RECRUITING

    Hamilton, Montana, 59840, United States